Vilhox-50 (Vildagliptin50mg) Tablets
Vildagliptin is an oral anti-diabetic agent thatenhances pancreatic islet cell responsiveness to glucose. Approximately 22,000patients and 7000 patient-years of exposure to vildagliptin has shown that theagent is well tolerated and efficacious in improving glycemic control inpatients with T2DM. Monotherapy trials have shown that significant HbA1clowering is accompanied by body weight-neutral and lipid-neutral effects, lowrisk of edema, and low risk of hypoglycemia. These characteristics makevildagliptin a favorable partner for combination therapy. Studies ofvildagliptin as an add-on to metformin have shown significant improvements inglycemic control (comparable to that of thiazolidinedione add-on), with thecombination being well tolerated and associated with low risks for hypoglycemiaand adverse effects on weight or lipid levels. Good tolerability and clinicallyrelevant improvements in glycemic control have also been observed with vildagliptinas an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatmentor in initial combination treatment with pioglitazone. Improved ÃÂ²-cell functionand glycemic control have been shown with vildagliptin in subjects withimpaired glucose tolerance and in T2DM patients with mild hyperglycemia, withsome evidence in the latter suggesting the potential for modifying diseasecourseÂ - Vasc Health Risk Manag. 2008 Dec; 4(6):1349-1360.